Autolus Therapeutics plc (AUTL) is a clinical-stage biopharmaceutical company focused on developing next-generation programmed T cell therapies for cancer treatment. The company's proprietary T-cell programming technology allows it to develop treatments that are designed to specifically target cancer cells while leaving healthy cells untouched.
Autolus Therapeutics has a pipeline of clinical-stage product candidates, including AUTO1, AUTO2, AUTO3, and AUTO4. AUTO1 and AUTO2 are being developed for the treatment of acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL), respectively. AUTO3 is being developed for the treatment of diffuse large B-cell lymphoma (DLBCL), and AUTO4 is being developed for the treatment of T-cell lymphoma.
The company's AUTO1 product candidate has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory ALL. Additionally, the FDA has granted orphan drug designation to AUTO1 for the treatment of ALL, and to AUTO3 for the treatment of DLBCL.
Autolus Therapeutics is headquartered in London, UK, and has operations in the United States. The company was founded in 2014 and went public in 2018.
|
